{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:24:01Z","timestamp":1791213841429,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute on Drug Abuse,United States","award":["DP2DA053720"],"award-info":[{"award-number":["DP2DA053720"]}]},{"name":"National Institute on Drug Abuse,United States","award":["DP2DA053720"],"award-info":[{"award-number":["DP2DA053720"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Xylazine is an alpha-2 adrenergic receptor agonist that has emerged as a contaminant in the illicit drug supply of fentanyl. Xylazine use may be suspected in naloxone-resistant overdoses and atypical, chronic wounds in people who use drugs (PWUD). This case is unique because it is the first case to our knowledge describing wound care for a xylazine-induced wound with a confirmatory xylazine test strip (XTS) in the setting of a syringe services program (SSP) and in the state of Florida.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 43-year-old woman with a past medical history of severe opioid use disorder and stimulant use disorder presented to a student-run clinic at a Miami SSP for wound care. She had multiple ulcerations diffusely over her bilateral forearms with surrounding erythema and warmth. Seven weeks later, she presented to clinic again for wound care because her wounds had progressed. At this visit, a XTS was used to confirm the presence of xylazine in her urine. Wound care management and harm reduction strategies employed at both visits were informed by best clinical judgement due to lack of formal guidelines at the time. Wound outcomes are unknown as the patient has not returned to clinic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Many PWUD at highest risk for acute and chronic health consequences of xylazine-adulterated fentanyl do not have access to healthcare outside of low barrier clinics and SSPs due to lack of insurance or mistrust of the traditional healthcare system due to stigma. There is an urgent need for access to XTS for PWUD and clinical practice guidelines for the treatment of xylazine-related wounds in outpatient clinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12954-024-00978-z","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:01:27Z","timestamp":1710471687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["A confirmed case of xylazine-induced skin ulcers in a person who injects drugs in Miami, Florida, USA"],"prefix":"10.1186","volume":"21","author":[{"given":"Peyton V.","family":"Warp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maia","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Serota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Ciraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irasema","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler S.","family":"Bartholomew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel E.","family":"Tookes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"978_CR1","doi-asserted-by":"publisher","unstructured":"Malayala SV, Papudesi BN, Bobb R, et al. Xylazine-Induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14(8). https:\/\/doi.org\/10.7759\/cureus.28160.","DOI":"10.7759\/cureus.28160"},{"key":"978_CR2","doi-asserted-by":"publisher","unstructured":"Gupta R, Holtgrave DR, Ashburn MA. Xylazine \u2014 Medical and Public Health imperatives. N Engl J Med Published Online April. 2023;26. https:\/\/doi.org\/10.1056\/NEJMp2303120.","DOI":"10.1056\/NEJMp2303120"},{"key":"978_CR3","doi-asserted-by":"publisher","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","volume":"233","author":"J Friedman","year":"2022","unstructured":"Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. https:\/\/doi.org\/10.1016\/j.drugalcdep.2022.109380.","journal-title":"Drug Alcohol Depend"},{"issue":"37","key":"978_CR4","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.15585\/mmwr.mm7037a5","volume":"70","author":"S Thangada","year":"2021","unstructured":"Thangada S, Clinton HA, Ali S, et al. Notes from the field: Xylazine, a Veterinary Tranquilizer, identified as an emerging novel substance in drug overdose deaths \u2014 Connecticut, 2019\u20132020. Morb Mortal Wkly Rep. 2021;70(37):1303\u20135. https:\/\/doi.org\/10.15585\/mmwr.mm7037a5.","journal-title":"Morb Mortal Wkly Rep"},{"key":"978_CR5","doi-asserted-by":"publisher","unstructured":"Madigan L, Bedard JG, Murray X-P, Huang et al. Xylazine is an agonist at kappa opioid receptors and exhibits sex-specific responses to naloxone administration. bioRxiv. Published online January 1, 2023:2023.09.08.556914. https:\/\/doi.org\/10.1101\/2023.09.08.556914.","DOI":"10.1101\/2023.09.08.556914"},{"key":"978_CR6","doi-asserted-by":"publisher","unstructured":"Dowton A, Doernberg M, Heiman E et al. Recognition and Treatment of Wounds in persons using xylazine: a Case Report from New Haven, Connecticut. J Addict Med.:https:\/\/doi.org\/10.1097\/ADM.0000000000001198. doi:10.1097\/ADM.0000000000001198.","DOI":"10.1097\/ADM.0000000000001198"},{"key":"978_CR7","unstructured":"Wallace L. A Case Of Skin Necrosis Caused By Intravenous Xylazine Abuse. J Hosp Med. Accessed May 11, 2023. https:\/\/shmabstracts.org\/abstract\/a-case-of-skin-necrosis-caused-by-intravenous-xylazine-abuse\/."},{"key":"978_CR8","doi-asserted-by":"publisher","unstructured":"Bishnoi A, Singh V, Khanna U, Vinay K. Skin ulcerations caused by xylazine: a less-known entity. J Am Acad Dermatol Published Online April. 2023;11. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.009.","DOI":"10.1016\/j.jaad.2023.04.009"},{"issue":"3","key":"978_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","volume":"89","author":"JC Reyes","year":"2012","unstructured":"Reyes JC, Negr\u00f3n JL, Col\u00f3n HM, et al. The Emerging of Xylazine as a New drug of abuse and its Health consequences among drug users in Puerto Rico. J Urban Health Bull N Y Acad Med. 2012;89(3):519\u201326. https:\/\/doi.org\/10.1007\/s11524-011-9662-6.","journal-title":"J Urban Health Bull N Y Acad Med"},{"key":"978_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jdcr.2023.04.010","volume":"36","author":"L Rose","year":"2023","unstructured":"Rose L, Kirven R, Tyler K, Chung C, Korman AM. Xylazine-induced acute skin necrosis in two patients who inject fentanyl. JAAD Case Rep. 2023;36:113\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2023.04.010.","journal-title":"JAAD Case Rep"},{"issue":"3","key":"978_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/add.15734","volume":"117","author":"N Maghsoudi","year":"2022","unstructured":"Maghsoudi N, Tanguay J, Scarfone K, et al. Drug checking services for people who use drugs: a systematic review. Addict Abingdon Engl. 2022;117(3):532\u201344. https:\/\/doi.org\/10.1111\/add.15734.","journal-title":"Addict Abingdon Engl"},{"issue":"1","key":"978_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12954-018-0213-2","volume":"15","author":"MS Krieger","year":"2018","unstructured":"Krieger MS, Yedinak JL, Buxton JA, et al. High willingness to use rapid fentanyl test strips among young adults who use drugs. Harm Reduct J. 2018;15(1):7. https:\/\/doi.org\/10.1186\/s12954-018-0213-2.","journal-title":"Harm Reduct J"},{"key":"978_CR13","unstructured":"Evaluation of Xylazine Test Strips (BTNX) for Drug Checking Purposes. Accessed February 20. 2024. https:\/\/www.cfsre.org\/nps-discovery\/drug-checking\/evaluation-of-xylazine-test-strips-btnx-for-drug-checking-purposes."},{"key":"978_CR14","doi-asserted-by":"publisher","unstructured":"Student-Run Free Clinic at a Syringe Services Program, Miami F. 2017\u20132019 | AJPH | Vol. 110 Issue 7. Accessed February 28, 2024. https:\/\/ajph.aphapublications.org\/doi\/abs\/https:\/\/doi.org\/10.2105\/AJPH.2020.305705?journalCode=ajph.","DOI":"10.2105\/AJPH.2020.305705?journalCode=ajph"},{"key":"978_CR15","doi-asserted-by":"publisher","first-page":"100209","DOI":"10.1016\/j.dadr.2023.100209","volume":"9","author":"MH Hauschild","year":"2023","unstructured":"Hauschild MH, Warp PV, Tookes HE, et al. Prevalence of xylazine among people who inject drugs seeking medical care at a syringe services program clinic: Miami, Florida, 2023. Drug Alcohol Depend Rep. 2023;9:100209. https:\/\/doi.org\/10.1016\/j.dadr.2023.100209.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"1","key":"978_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0379-0738(03)00083-5","volume":"134","author":"ME Stillwell","year":"2003","unstructured":"Stillwell ME. A reported case involving impaired driving following self-administration of xylazine. Forensic Sci Int. 2003;134(1):25\u20138. https:\/\/doi.org\/10.1016\/s0379-0738(03)00083-5.","journal-title":"Forensic Sci Int"},{"key":"978_CR17","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.dadr.2022.100074","volume":"4","author":"MK Reed","year":"2022","unstructured":"Reed MK, Imperato NS, Bowles JM, Salcedo VJ, Guth A, Rising KL. Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips. Drug Alcohol Depend Rep. 2022;4:100074. https:\/\/doi.org\/10.1016\/j.dadr.2022.100074.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"8","key":"978_CR18","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","volume":"112","author":"RS Alexander","year":"2022","unstructured":"Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and overdoses: Trends, concerns, and recommendations. Am J Public Health. 2022;112(8):1212\u20136. https:\/\/doi.org\/10.2105\/AJPH.2022.306881.","journal-title":"Am J Public Health"},{"key":"978_CR19","doi-asserted-by":"publisher","unstructured":"In Support of Community Drug Checking Programs: Position Statement of AMERSA, Inc. (Association for Multidisciplinary Education and Research in Substance use and Addiction) - Katherine Hill, Katherine Dunham, Zoe Brokos, Jenna L. Butner, Ilana Hull, Kimberly L. Sue, Li Li, Kinna Thakarar. 2024. Accessed February 21, 2024. https:\/\/journals-sagepub-com.access.library.miami.eduhttps:\/\/doi.org\/10.1177\/29767342231212787.","DOI":"10.1177\/29767342231212787"},{"key":"978_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States. Int J Drug Policy. 2019;63:122\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.007.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"978_CR21","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1080\/07853890.2021.1993326","volume":"53","author":"DP Serota","year":"2021","unstructured":"Serota DP, Tookes HE, Hervera B, et al. Harm reduction for the treatment of patients with severe injection-related infections: description of the Jackson SIRI Team. Ann Med. 2021;53(1):1960\u20138. https:\/\/doi.org\/10.1080\/07853890.2021.1993326.","journal-title":"Ann Med"},{"issue":"1","key":"978_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/ADM.0000000000001245","volume":"18","author":"R McFadden","year":"2024","unstructured":"McFadden R, Wallace-Keeshen S, Petrillo Straub K, et al. Xylazine-associated wounds: clinical experience from a low-barrier Wound Care Clinic in Philadelphia. J Addict Med. 2024;18(1):9. https:\/\/doi.org\/10.1097\/ADM.0000000000001245.","journal-title":"J Addict Med"},{"key":"978_CR23","unstructured":"Best A, Silva DTD. Substance Use Prevention and Harm Reduction."},{"key":"978_CR24","unstructured":"Xylazine. What Clinicians Need to Know."},{"key":"978_CR25","unstructured":"IDHS: Illinois Xylazine Best Practices for Health Care Providers. Accessed February 21. 2024. https:\/\/www.dhs.state.il.us\/page.aspx?item=154552."},{"issue":"5","key":"978_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/1523-1747.ep12476467","volume":"91","author":"M Dyson","year":"1988","unstructured":"Dyson M, Young S, Pendle CL, Webster DF, Lang SM. Comparison of the effects of moist and dry conditions on dermal repair. J Invest Dermatol. 1988;91(5):434\u20139. https:\/\/doi.org\/10.1111\/1523-1747.ep12476467.","journal-title":"J Invest Dermatol"},{"key":"978_CR27","doi-asserted-by":"publisher","unstructured":"Vogt PM, Andree C, Breuing K et al. Dry, moist, and wet skin wound repair. Ann Plast Surg. 1995;34(5):493\u2013499; discussion 499\u2013500. https:\/\/doi.org\/10.1097\/00000637-199505000-00007.","DOI":"10.1097\/00000637-199505000-00007"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-00978-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-00978-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T03:05:28Z","timestamp":1710471928000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-00978-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-00978-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3194876\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors of the present manuscript declare that they have no conflicts of interest. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee(s) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. Written informed consent for the publication of her clinical details and clinical image was obtained from the patient. A copy of the consent form is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"There are no competing interests to report for this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}